1. Successful Control of Dasatinib-related Chylothorax by the Japanese Herbal Medicine 'Goreisan'
- Author
-
Akihiko Kawana, Yohei Maki, Nobuyoshi Hayashi, Jun Miyata, Yuji Fujikura, Yoichi Tagami, Takayuki Yamamoto, Tomoya Sano, Chie Watanabe, Shinichiro Ota, Yosuke Okada, Hisashi Sasaki, Hiraku Ogata, and Yoshifumi Kimizuka
- Subjects
Adult ,Male ,medicine.medical_specialty ,Water flow ,Dasatinib ,Antineoplastic Agents ,Case Report ,030204 cardiovascular system & hematology ,Chylothorax ,03 medical and health sciences ,0302 clinical medicine ,Refractory ,chronic myeloid leukemia ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,hemic and lymphatic diseases ,Internal Medicine ,Humans ,Medicine ,Effective treatment ,Goreisan ,Intensive care medicine ,Adverse effect ,Aged ,Aged, 80 and over ,Plant Extracts ,business.industry ,Myeloid leukemia ,General Medicine ,Middle Aged ,medicine.disease ,Pleural Effusion ,aquaporin ,Female ,Radiography, Thoracic ,030211 gastroenterology & hepatology ,Medicine, Kampo ,business ,Phytotherapy ,medicine.drug - Abstract
Dasatinib-related chylothorax is a rare adverse event, and the mechanism underlying its occurrence is still not fully understood. We herein report the case of a 73-year-old woman with chronic myeloid leukemia (CML) who developed dasatinib-related chylothorax refractory to conventional treatments, except for steroids. To the best of our knowledge, this is the first case of dasatinib-related chylothorax which was successfully controlled by combining diuretics with the Japanese herbal medicine “Goreisan.” “Goreisan” is known to inhibit aquaporin channels and regulate the water flow. Our findings showed that “Goreisan” is an effective treatment option for uncontrollable dasatinib-related chylothorax.
- Published
- 2019